Binimetinib: all 101 studies that test it
Page 1 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic CancerRecruitingNCT06159478Phase 2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaRecruitingNCT05286788Phase 2
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingNCT05203172Phase 4
- Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingNCT05026983Phase 2
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingNCT04720768Phase 1/2
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingNCT04598009Phase 2
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
- Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantRecruitingNCT04322383Phase 2
- Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
- Bioequivalence Binimetinib 3 x 15 mg and 45 mg FormulationsCompletedNCT05810740Phase 1Results posted
- Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)TerminatedNCT05554354Phase 2Results posted
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedNCT04585815Phase 1/2Results posted
- Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingNCT04439344Phase 2Results posted
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E MutationTerminatedNCT04390243Phase 2Results posted
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedNCT04221438Phase 2Results posted
- Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal CancerCompletedNCT03981614Phase 2Results posted
- Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGGTerminatedNCT03973918Phase 2Results posted
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerCompletedNCT03915951Phase 2Results posted
- An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisTerminatedNCT03911869Phase 2Results posted
- Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the BrainCompletedNCT03898908Phase 2Results posted
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsCompletedNCT03864042Phase 1Results posted
- A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant CancersCompletedNCT03843775Phase 1/2Results posted
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedNCT03693170Phase 2Results posted
- Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted
- Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)CompletedNCT03374254Phase 1Results posted
- Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationCompletedNCT03271047Phase 2Results posted
- Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform NeurofibromasCompletedNCT03231306Phase 2Results posted
- Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT03106415Phase 1/2Results posted
- Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerCompletedNCT02928224Phase 3Results posted
- Study of MEK162 for Children With Low-Grade GliomasCompletedNCT02285439Phase 1/2Results posted
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
- A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the LungCompletedNCT02185690Phase 1Results posted
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
- Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticCompletedNCT02094872Phase 2Results posted
- MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyTerminatedNCT02089230Phase 1/2Results posted
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS TumorsCompletedNCT01927341Phase 1/2Results posted
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaCompletedNCT01909453Phase 3Results posted
- MEK162 for Patients With RAS/RAF/MEK Activated TumorsCompletedNCT01885195Phase 2Results posted
- A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
- First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract CarcinomaCompletedNCT01828034Phase 1/2Results posted
- A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaTerminatedNCT01801358Phase 1/2Results posted
- A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant MelanomaCompletedNCT01781572Phase 1/2Results posted
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaCompletedNCT01763164Phase 3Results posted
- A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsCompletedNCT01543698Phase 1/2Results posted
- A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaCompletedNCT01320085Phase 2Results posted
- A Study of ARRY-438162 in Patients With Rheumatoid ArthritisCompletedNCT00650767Phase 2Results posted
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingNCT05564403Phase 2
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
- Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal CancerCompletedNCT05510895Phase 2
- Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedNCT05304546Phase 2
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Active, not recruitingNCT05270044Phase 3
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Phase 2
- Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaActive, not recruitingNCT05170334Phase 2
- Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg FormulationsStatus unknownNCT05103891Phase 1
- Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT05080621Phase 1/2
- Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingNCT04657991Phase 3
- ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingNCT04526782Phase 2
- Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
- Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLActive, not recruitingNCT04324112Phase 2
- Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic CancerCompletedNCT04132505Phase 1
- Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerActive, not recruitingNCT04061980Phase 2
- Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
- Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerTerminatedNCT04005144Phase 1
- Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT03991819Phase 1
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2
- Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminatedNCT03878719Phase 1
- Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsActive, not recruitingNCT03839342Phase 2
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
- Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT03170206Phase 1
- A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT03158103Phase 1
- Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.CompletedNCT02964689Phase 1
- Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
- Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
- BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)CompletedNCT02834364Phase 2
- MEK162 in Combination With Capecitabine in Advanced Biliary Tract CancerCompletedNCT02773459Phase 1/2
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
- A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal CancersCompletedNCT02613650Phase 1
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung CancerWithdrawnNCT02451865Phase 1
- Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsWithdrawnNCT02263898Phase 2
- An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
- A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary CancerWithdrawnNCT02105350Phase 1
- MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionTerminatedNCT02050815Phase 1
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
- MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal CancerCompletedNCT02041481Phase 1
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT01991379Phase 1/2
- A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationCompletedNCT01859026Phase 1
- A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT01649336Phase 1
- A Study of MEK162 and AMG 479 in Patients With Selected Solid TumorsTerminatedNCT01562899Phase 1/2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic CardiomyopathyWithdrawnNCT01556568Phase 2
- A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid TumorsCompletedNCT01469130Phase 1
- A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid TumorsCompletedNCT01449058Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01363232Phase 1
- MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E MutationsCompletedNCT01352273Phase 1
- Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01337765Phase 1